CD226 and acute myeloid leukemia: Interestingly, low levels of DNAM-1 expression are observed in AML patients, while its ligands are highly expressed [17, 18] suggesting that the binding of TIGIT with CD112 and CD155 ligands may represent a mechanism of tumor immune escape promoted by immune cell inhibitory signaling.